Currently Empty: $0.00
A mitochondria-targeting tetrapeptide that concentrates in the inner mitochondrial membrane, developed through multiple Phase II and Phase III clinical trials.
$310.00
A mitochondria-targeting tetrapeptide that concentrates in the inner mitochondrial membrane, developed through multiple Phase II and Phase III clinical trials.
$579.00
A mitochondria-targeting tetrapeptide that concentrates in the inner mitochondrial membrane, developed through multiple Phase II and Phase III clinical trials.
$190.00
A stabilised GHRH analogue approved by the FDA for the reduction of excess visceral abdominal fat, and one of the best-evidenced compounds in the portfolio.
$130.00
A naturally occurring thymic peptide licensed as a medicine in more than thirty countries, with the broadest formal regulatory footprint in this portfolio.
$598.80
A naturally occurring thymic peptide licensed as a medicine in more than thirty countries, with the broadest formal regulatory footprint in this portfolio.
$130.00
A synthetic fragment of thymosin beta-4, an actin-binding protein central to cell migration and tissue repair.
$429.00
A synthetic fragment of thymosin beta-4, an actin-binding protein central to cell migration and tissue repair.
$190.00
A synthetic fragment of thymosin beta-4, an actin-binding protein central to cell migration and tissue repair.
$99.00
A fixed combination of the two most widely used regenerative peptides, pairing an angiogenic and a cell-migration mechanism.
$499.00